Enzo Biochem Reports That Its Clinical Labs Division Ha
Available Newly Authorized Swine Flu (H1N1) Test
January 13, 2010 11:03 AM Eastern Time
NEW YORK--(EON: Enhanced Online News)--Enzo Biochem, Inc. (NYSE: ENZ) announced today that its Enzo Clinical Labs d
become one of the first diagnostic laboratories to make available a rapid and sensitive H1N1 PCR test for the swine flu virus. Enzo
serves physicians throughout the Metropolitan New York area, as well as New Jersey and parts of Pennsylvania.
“The introduction of this test, within a few days after it had received FDA clearance, is indicative of the capabilities of Enzo’s clinical
division in being able to commercialize new tests,” said Kevin Krenitsky, MD, President of Enzo Clinical Labs.
The H1N1 identification is very specific, without cross-detection of other influenza variant subtypes, said Dr. Krenitsky.
The swine flu is caused by the H1N1 type of influenza virus. In the US, more than 22 million people have been infected with, and as
individuals have died as a result of, this new influenza pandemic virus. The test that is now available enables physicians to differentiat
with the 2009 H1N1 virus from other strains that show similar symptoms, thus allowing appropriate management of the patient sym
Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological proc
research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical communi
founding in 1976, our strategic focus has been on the development of enabling technologies in the life sciences field. Enzo Life Scien
produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research
Its catalog of over 40,000 products serve the molecular biology, drug discovery and pathology research markets worldwide. Enzo
division provides laboratory services for a growing roster of physicians in the New Y